Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, ...

Optimizing bispecific AE management in the community requires a combination of standardized clinical protocols, reliable educational tools, and robust communication networks with academic partners.

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Boehringer Ingelheim announced a license and collaboration agreement with Simcere Pharmaceuticals to develop Simcere’s ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that Janssen Biotech, ...

The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs.

In this case, one arm of the antibody binds to an infected cell carrying cytomegalovirus proteins. The other arm attaches directly to a T cell. The antibody acts as a physical bridge, pulling the T ...